Tags

Type your tag names separated by a space and hit enter

Coenzyme Q10 treatment in infertile men with idiopathic asthenozoospermia: a placebo-controlled, double-blind randomized trial.
Fertil Steril. 2009 May; 91(5):1785-92.FS

Abstract

OBJECTIVE

To evaluate the effectiveness of coenzyme Q(10) treatment in improving semen quality in men with idiopathic infertility.

DESIGN

Placebo-controlled, double-blind randomized trial.

SETTING

Andrology Unit, Department of Internal Medicine, Polytechnic University of Marche, Italy.

PATIENT(S)

Sixty infertile patients (27-39 years of age) with the following baseline sperm selection criteria: concentration >20 x 10(6)/mL, sperm forward motility <50%, and normal sperm morphology >30%; 55 patients completed the study.

INTERVENTION(S)

Patients underwent double-blind therapy with coenzyme Q(10), 200 mg/day, or placebo; the study design was 1 month of run-in, 6 months of therapy or placebo, and 3 months of follow-up.

MAIN OUTCOME MEASURE(S)

Variations in semen parameters used for patient selection and variations of coenzyme Q(10) and ubiquinol concentrations in seminal plasma and spermatozoa.

RESULT(S)

Coenzyme Q(10) and ubiquinol increased significantly in both seminal plasma and sperm cells after treatment, as well as spermatozoa motility. A weak linear dependence among the relative variations, baseline and after treatment, of seminal plasma or intracellular coenzyme Q(10) and ubiquinol levels and kinetic parameters was found in the treated group. Patients with a lower baseline value of motility and levels of coenzyme Q(10) had a statistically significant higher probability to be responders to the treatment.

CONCLUSION(S)

The exogenous administration of coenzyme Q(10) increases the level of the same and ubiquinol in semen and is effective in improving sperm kinetic features in patients affected by idiopathic asthenozoospermia.

Authors+Show Affiliations

Department of Internal Medicine and Applied Biotechnologies, Andrology Unit, Endocrinology, Umberto I Hospital, School of Medicine, Polytechnic University of Marche, Ancona, Italy. g.balercia@ao-umbertoprimo.marche.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

18395716

Citation

Balercia, Giancarlo, et al. "Coenzyme Q10 Treatment in Infertile Men With Idiopathic Asthenozoospermia: a Placebo-controlled, Double-blind Randomized Trial." Fertility and Sterility, vol. 91, no. 5, 2009, pp. 1785-92.
Balercia G, Buldreghini E, Vignini A, et al. Coenzyme Q10 treatment in infertile men with idiopathic asthenozoospermia: a placebo-controlled, double-blind randomized trial. Fertil Steril. 2009;91(5):1785-92.
Balercia, G., Buldreghini, E., Vignini, A., Tiano, L., Paggi, F., Amoroso, S., Ricciardo-Lamonica, G., Boscaro, M., Lenzi, A., & Littarru, G. (2009). Coenzyme Q10 treatment in infertile men with idiopathic asthenozoospermia: a placebo-controlled, double-blind randomized trial. Fertility and Sterility, 91(5), 1785-92. https://doi.org/10.1016/j.fertnstert.2008.02.119
Balercia G, et al. Coenzyme Q10 Treatment in Infertile Men With Idiopathic Asthenozoospermia: a Placebo-controlled, Double-blind Randomized Trial. Fertil Steril. 2009;91(5):1785-92. PubMed PMID: 18395716.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Coenzyme Q10 treatment in infertile men with idiopathic asthenozoospermia: a placebo-controlled, double-blind randomized trial. AU - Balercia,Giancarlo, AU - Buldreghini,Eddi, AU - Vignini,Arianna, AU - Tiano,Luca, AU - Paggi,Francesca, AU - Amoroso,Salvatore, AU - Ricciardo-Lamonica,Giuseppe, AU - Boscaro,Marco, AU - Lenzi,Andrea, AU - Littarru,GianPaolo, Y1 - 2008/04/08/ PY - 2007/12/12/received PY - 2008/02/04/revised PY - 2008/02/12/accepted PY - 2008/4/9/pubmed PY - 2009/5/20/medline PY - 2008/4/9/entrez SP - 1785 EP - 92 JF - Fertility and sterility JO - Fertil. Steril. VL - 91 IS - 5 N2 - OBJECTIVE: To evaluate the effectiveness of coenzyme Q(10) treatment in improving semen quality in men with idiopathic infertility. DESIGN: Placebo-controlled, double-blind randomized trial. SETTING: Andrology Unit, Department of Internal Medicine, Polytechnic University of Marche, Italy. PATIENT(S): Sixty infertile patients (27-39 years of age) with the following baseline sperm selection criteria: concentration >20 x 10(6)/mL, sperm forward motility <50%, and normal sperm morphology >30%; 55 patients completed the study. INTERVENTION(S): Patients underwent double-blind therapy with coenzyme Q(10), 200 mg/day, or placebo; the study design was 1 month of run-in, 6 months of therapy or placebo, and 3 months of follow-up. MAIN OUTCOME MEASURE(S): Variations in semen parameters used for patient selection and variations of coenzyme Q(10) and ubiquinol concentrations in seminal plasma and spermatozoa. RESULT(S): Coenzyme Q(10) and ubiquinol increased significantly in both seminal plasma and sperm cells after treatment, as well as spermatozoa motility. A weak linear dependence among the relative variations, baseline and after treatment, of seminal plasma or intracellular coenzyme Q(10) and ubiquinol levels and kinetic parameters was found in the treated group. Patients with a lower baseline value of motility and levels of coenzyme Q(10) had a statistically significant higher probability to be responders to the treatment. CONCLUSION(S): The exogenous administration of coenzyme Q(10) increases the level of the same and ubiquinol in semen and is effective in improving sperm kinetic features in patients affected by idiopathic asthenozoospermia. SN - 1556-5653 UR - https://www.unboundmedicine.com/medline/citation/18395716/Coenzyme_Q10_treatment_in_infertile_men_with_idiopathic_asthenozoospermia:_a_placebo_controlled_double_blind_randomized_trial_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0015-0282(08)00487-1 DB - PRIME DP - Unbound Medicine ER -